Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 26.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Weller, Michael; Weber, Ruthild G; Willscher, Edith; Riehmer, Vera; Hentschel, Bettina; Kreuz, Markus; Felsberg, Jörg; Beyer, Ulrike; Löffler-Wirth, Henry; Kaulich, Kerstin; Steinbach, Joachim P; Hartmann, Christian; Gramatzki, D; Schramm, J; Westphal, M; Schackert, G; Simon, M; Martens, T; Boström, J; Hagel, C; Sabel, M; Krex, D; Tonn, J C; Wick, W; Noell, S; Schlegel, U; Radlwimmer, B; Pietsch, T; Loeffler, M; von Deimling, A; Binder, H; Reifenberger, G (2015). Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 129(5):679-693.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Suchorska, B; Jansen, N L; Linn, J; Kretzschmar, H; Janssen, H; Eigenbrod, S; Simon, M; Pöpperl, G; Kreth, F W; la Fougere, C; Weller, M; Tonn, J C (2015). Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 84(7):710-719.

Thon, N; Kunz, M; Lemke, L; Jansen, N L; Eigenbrod, S; Kreth, S; Lutz, J; Egensperger, R; Giese, A; Herms, J; Weller, M; Kretzschmar, H; Tonn, J C; laFougère, C; Kreth, F W (2015). Dynamic (18) F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 136(9):2132-2145.

Langen, K J; Tonn, J C; Weller, M; Galldiks, N (2014). Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. Journal of Neuro-Oncology, 120(3):665-666.

Weller, M; van den Bent, M; Hopkins, K; Tonn, J C; Stupp, R; Falini, A; Cohen-Jonathan-Moyal, E; Frappaz, D; Henriksson, R; Balana, C; Chinot, O; Ram, Z; Reifenberger, G; Soffietti, R; Wick, W (2014). EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, 15(9):e395-e403.

Weller, M; Kaulich, K; Hentschel, B; Felsberg, J; Gramatzki, D; Pietsch, T; Simon, M; Westphal, M; Schackert, G; Tonn, J C; von Deimling, A; Davis, T; Weiss, W A; Loeffler, M; Reifenberger, G (2014). Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 134(10):2437-2447.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Blaes, J; Weiler, M; Sahm, F; Hentschel, B; Osswald, M; Czabanka, M; Thomé, C M; Schliesser, M G; Pusch, S; Luger, S; Winkler, F; Radbruch, A; Jugold, M; Simon, M; Steinbach, J P; Schackert, G; Tatagiba, M; Westphal, M; Tonn, J C; Gramatzki, D; Pietsch, T; Hartmann, C; Glimm, H; Vajkoczy, P; von Deimling, A; Platten, M; Weller, M; Wick, W (2014). NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 117(1):25-32.

Heese, O; Vogeler, E; Martens, T; Schnell, O; Tonn, J C; Simon, M; Schramm, J; Krex, D; Schackert, G; Reithmeier, T; Nikkhah, G; Sabel, M; Steiger, H J; Schlegel, U; Löffler, M; Weller, M; Westphal, M (2013). End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro-Oncology, 15(9):1251-1256.

Kreth, F W; Thon, N; Simon, M; Westphal, M; Schackert, G; Nikkhah, G; Hentschel, B; Reifenberger, G; Pietsch, T; Weller, M; Tonn, J C (2013). Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Annals of Oncology, 24(12):3117-3123.

Hartmann, C; Hentschel, B; Simon, M; Westphal, M; Schackert, G; Tonn, J C; Loeffler, M; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M (2013). Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clinical Cancer Research, 19(18):5146-5157.

Capper, D; Simon, M; Langhans, C D; Okun, J G; Tonn, J C; Weller, M; von Deimling, A; Hartmann, C (2012). 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. International Journal of Cancer, 131(3):766-768.

Weller, M; Stupp, R; Hegi, M E; van den Bent, M; Tonn, J C; Sanson, M; Wick, W; Reifenberger, G (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14(Suppl. 4):iv100-iv108.

Wick, W; Tonn, J C; Weller, M (2012). Primäre intrakranielle und spinale Tumoren. In: Brandt, T; Diener, H S; Gerloff, C. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart: Kohlhammer, 813-847.

Reardon, D A; Neyns, B; Weller, M; Tonn, J C; Nabors, L B; Stupp, R (2011). Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 7(3):339-354.

Felsberg, J; Thon, N; Eigenbrod, S; Hentschel, B; Sabel, M C; Westphal, M; Schackert, G; Kreth, F W; Pietsch, T; Löffler, M; Weller, M; Reifenberger, G; Tonn, J C (2011). Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International Journal of Cancer, 129(3):659-670.

Tabatabai, G; Tonn, J C; Stupp, R; Weller, M (2011). The role of integrins in glioma biology and anti-glioma therapies. Current Pharmaceutical Design, 17(23):2402-2410.

Heese, O; Schmidt, M; Nickel, S; Berger, H; Goldbrunner, R; Tonn, J C; Bhär, O; Steinbach, J P; Simon, M; Schramm, J; Krex, D; Schackert, G; Reithmeier, T; Nikkhah, G; Löffler, M; Weller, M; Westphal, M (2010). Complementary therapy use in patients with glioma: an observational study. Neurology, 75(24):2229-2235.

Tabatabai, G; Stupp, R; van den Bent, M J; Hegi, M E; Tonn, J C; Wick, W; Weller, M (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 120(5):585-592.

Hofer, S; Happold, C; Weller, M (2010). Oligodendroglioma. In: Tonn, J C; Westphal, M; Rutka, J T. Oncology of CNS Tumors. Berlin, Heidelberg : Springer, 163-170.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 28(16):2712-2718.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M J; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Reply to M.C. Chamberlain. Journal of Clinical Oncology, 28(33):e696-e697.

Weller, M; Felsberg, J; Hartmann, C; Berger, H; Steinbach, J P; Schramm, J; Westphal, M; Schackert, G; Simon, M; Tonn, J C; Heese, O; Krex, D; Nikkhah, G; Pietsch, T; Wiestler, O; Reifenberger, G; von Deimling, A; Loeffler, M (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of Clinical Oncology, 27(34):5743-5750.

Weller, M; Tonn, J C; Ernemann, U; Wiestler, O D; Bamberg, M (2009). Glioblastome : Aktuelle Standards bei Diagnostik und Therapie. Best Practice Onkologie, 4(2):4-11.

This list was generated on Mon Nov 20 11:02:15 2017 CET.